The city of Baltimore has filed a lawsuit against Biogen, accusing the pharmaceutical company of engaging in an “unlawful” scheme with pharmacy benefit managers to block generic competition for their multiple sclerosis treatment, Tecfidera. Biogen’s plan to introduce a new version of the drug called Vumerity was thwarted when its patents were declared invalid during patent litigation with generic companies. The lawsuit alleges that only 1% of Tecfidera patients had switched to Vumerity at the time of the patent expiration. This legal action adds to the growing scrutiny of pharmaceutical companies’ tactics to maintain market monopolies on lucrative drugs.
Source link
Baltimore says Biogen ‘bribed’ PBMs to favor its pricey MS drug over generics
